Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bupivacaine hydrochloride + isopropyl alcohol + povidone-iodine + dexamethasone sodium
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Topical, Parenteral
01
Overview
This appears to refer to a **compounded or kit-based combination product** built around **bupivacaine hydrochloride** for local or regional anesthesia/analgesia, with **dexamethasone sodium** as an anti-inflammatory and analgesia-prolonging adjuvant, plus **povidone-iodine** and **isopropyl alcohol** as antiseptic components used for procedural skin preparation rather than direct anesthetic pharmacology. Publicly visible sources support closely related kit products combining bupivacaine hydrochloride with povidone-iodine and isopropyl alcohol, and a separate kit product combining **dexamethasone sodium phosphate**, bupivacaine hydrochloride, and povidone-iodine; however, I did not identify a clearly verifiable public source for this exact four-component name using **dexamethasone sodium** as written. Mechanistically, the clinically meaningful therapeutic activity would primarily come from voltage-gated sodium channel blockade by bupivacaine, with dexamethasone serving as an adjunct to reduce inflammation and potentially prolong postoperative analgesia.
- Other names
- bupivacaine hydrochloride + isopropyl alcohol + povidone-iodine + dexamethasone sodium
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)KCNMA1 (Calcium-activated potassium channel subfamily M alpha member 1)GR (Glucocorticoid receptor)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on bupivacaine hydrochloride + isopropyl alcohol + povidone-iodine + dexamethasone sodium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bupivacaine hydrochloride + isopropyl alcohol + povidone-iodine + dexamethasone sodium.